Treatment for infections with carbapenem-resistant Enterobacteriaceae: What options do we still have?

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Yamamoto, Michele ^a,b   Pop Vicas, Aurora E ^a,b  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; BIAPENEM; CARBAPENEM; CARBAPENEM DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TIGECYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTEREMIA; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CARBAPENEM RESISTANT ENTEROBACTERIACEAE INFECTION; ENTEROBACTERIACEAE INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; HEALTH; MICROBIOLOGY; PATHOGENICITY; PROCEDURES;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GLOBAL HEALTH; HUMANS; INFECTION CONTROL;

EID: 84903384329     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13949     Document Type: Review

References (62)

1. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012, 18:268-281. 10.1111/j.1469-0691.2011.03570.x, 21793988.
2. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106. 10.1086/592412, 18973455.
3. Snitkin ES, Zelazny AM, Thomas PJ, Stock F, Henderson DK, Palmore TN, Segre JA. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012, 4:148ra116. 3521604, 22914622.
4. Evans HL, Lefrak SN, Lyman J, Smith RL, Chong TW, McElearney ST, Schulman AR, Hughes MG, Raymond DP, Pruett TL, Sawyer RG. Cost of Gram-negative resistance. Crit Care Med 2007, 35:89-95. 10.1097/01.CCM.0000251496.61520.75, 17110877.
5. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007, 20:440-458. table of contents, 10.1128/CMR.00001-07, 1932750, 17630334.
6. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013, 13:785-796. 10.1016/S1473-3099(13)70190-7, 23969216.
7. Bratu S, Tolaney P, Karumudi U, Quale J, Mooty M, Nichani S, Landman D. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005, 56:128-132. 10.1093/jac/dki175, 15917285.
8. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17:1791-1798. 10.3201/eid1710.110655, 3310682, 22000347.
9. Centers for Disease Control and Prevention (CDC) Notes from the Field: New Delhi metallo-β-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography - Illinois, 2013. MMWR Morb Mortal Wkly Rep 2014, 62:1051. Centers for Disease Control and Prevention (CDC).
10. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707. 10.1128/CMR.05035-11, 3485753, 23034326.
11. Zavascki AP, Barth AL, Gaspareto PB, Goncalves AL, Moro AL, Fernandes JF, Goldani LZ. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J Antimicrob Chemother 2006, 58:882-885. 10.1093/jac/dkl327, 16895936.
12. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011, 37:415-419. 10.1016/j.ijantimicag.2011.01.012, 21429716.
13. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev 1956, 20:14-27. 180843, 13303920.
14. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190. 10.1128/JCM.39.1.183-190.2001, 87699, 11136768.
15. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194-199. 10.1016/j.ijantimicag.2009.10.005, 20006471.
16. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhão RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013, 57:524-531. 10.1093/cid/cit334, 23697744.
17. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 2012, 54:1720-1726. 10.1093/cid/cis286, 3357480, 22423120.
18. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011, 55:3284-3294. 10.1128/AAC.01733-10, 3122440, 21555763.
19. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436. 10.1128/AAC.01361-08, 2715599, 19433570.
20. Roberts JA, Lipman J. Editorial commentary: Closing the loop - a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis 2012, 54:1727-1729. 10.1093/cid/cis311, 22423122.
21. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011, 17:1798-1803. 10.1111/j.1469-0691.2011.03514.x, 21595793.
22. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012, 56:2108-2113. 10.1128/AAC.06268-11, 3318350, 22252816.
23. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012, 55:943-950. 10.1093/cid/cis588, 22752516.
24. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728. 10.1086/599225, 19438394.
25. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, Doi Y. Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. Clin Infect Dis 2011, 53:373-376. 10.1093/cid/cir401, 3202324, 21810751.
26. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J Hosp Infect 2010, 76:70-73. 10.1016/j.jhin.2010.03.021, 20705205.
27. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008, 21:449-465. 10.1128/CMR.00006-08, 2493081, 18625681.
28. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L, Barth AL, Ramos F, Boniatti MM, Nation RL, Li J. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008, 47:1298-1304. 10.1086/592577, 18840079.
29. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, Cipullo R, Moreira JC, Baia C, Barbosa V, Abboud CS. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis 2012, 14:198-205. 10.1111/j.1399-3062.2011.00688.x, 22093103.
30. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009, 47:1611-1612. 10.1128/JCM.02466-08, 2681849, 19261795.
31. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?. Clin Microbiol Infect 2011, 17:1135-1141. 10.1111/j.1469-0691.2011.03553.x, 21635663.
32. Levy Hara G, Gould I, Endimiani A, Pardo PR, Daikos G, Hsueh PR, Mehtar S, Petrikkos G, Casellas JM, Daciuk L, Paciel D, Novelli A, Saginur R, Pryluka D, Medina J, Savio E. Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. J Chemother 2013, 25:129-140. 10.1179/1973947812Y.0000000062, 23783137.
33. Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, Casini B, Tascini C, Menichetti F. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013, 56:697-700. 10.1093/cid/cis969, 23155147.
34. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010, 16:184-186. 10.1111/j.1469-0691.2009.02921.x, 19694767.
35. Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014, 43:52-59. 10.1016/j.ijantimicag.2013.09.010, 24183799.
36. Alexander BT, Marschall J, Tibbetts RJ, Neuner EA, Dunne WM, Ritchie DJ. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. Clin Ther 2012, 34:1314-1323. 10.1016/j.clinthera.2012.05.002, 22691610.
37. Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, Jenkins SG, Calfee DP. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother 2011, 55:5893-5899. 10.1128/AAC.00387-11, 3232750, 21968368.
38. Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2011, 55:3002-3004. 10.1128/AAC.01420-10, 3101469, 21422205.
39. Giamarellou H, Galani L, Baziaka F, Karaiskos I. Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:2388-2390. 10.1128/AAC.02399-12, 3632902, 23439635.
40. Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, Venditti M. Successful ertapenem-doripenem combination treatment of bacteremic ventilator-associated pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2013, 57:2900-2901. 10.1128/AAC.00188-13, 3716145, 23571536.
41. Karaiskos I, Masgala A, Galani L, Baziaka F, Giamarellou H. Double carbapenems regimens for infections in humans due to carbapenemase-producing Klebsiella pneumonia (CPKP). Denver, CO, USA: Paper presented at 53rd Interscience Conference in Antimicrobial Agents and Chemotherapy (ICAAC), Poster K-186.
42. Sader HS, Farrell DJ, Jones RN. Tigecycline activity tested against multidrug-resistant Enterobacteriaceae and Acinetobacter spp. isolated in US medical centers (2005-2009). Diagn Microbiol Infect Dis 2011, 69:223-227. 10.1016/j.diagmicrobio.2010.10.020, 21251571.
43. Guner R, Hasanoglu I, Keske S, Kalem AK, Tasyaran MA. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 2011, 39:515-518. 10.1007/s15010-011-0161-1, 21789524.
44. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012, 11:32. 10.1186/1476-0711-11-32, 3552987, 23234297.
45. Lee YT, Tsao SM, Hsueh PR. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 2013, 32:1211-1220. 10.1007/s10096-013-1870-4, 23553594.
46. Kontopidou F, Giamarellou H, Katerelos P, Maragos A, Kioumis I, Trikka-Graphakos E, Valakis C, Maltezou HC. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect 2014, 20:O117-O123. 10.1111/1469-0691.12341, 23992130.
47. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011, 55:1162-1172. 10.1128/AAC.01402-10, 3067123, 21173186.
48. Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012, 54:1699-1709. 10.1093/cid/cis270, 3404716, 22467668.
49. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011, 11:834-844. 10.1016/S1473-3099(11)70177-3, 21784708.
50. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, . 311 Study Group Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010, 68:140-151. 10.1016/j.diagmicrobio.2010.05.012, 20846586, 311 Study Group.
51. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol 2009, 47:1613. 10.1128/JCM.00404-09, 2681882, 19403778.
52. Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013, 57:1756-1762. 10.1128/AAC.01232-12, 3623336, 23357775.
53. FDA Drug Safety Communication Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. [http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm], FDA Drug Safety Communication.
54. FDA Drug Safety Communication FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. [http://www.fda.gov/drugs/drugsafety/ucm369580.htm], FDA Drug Safety Communication.
55. Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, Jacobs MR, Bonomo RA. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother 2010, 54:526-529. 10.1128/AAC.01235-09, 2798518, 19901089.
56. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009, 34:506-515. 10.1016/j.ijantimicag.2009.08.013, 19828298.
57. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011, 15:e732-e739. 10.1016/j.ijid.2011.07.007, 21945848.
58. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J Antimicrob Chemother 2012, 67:2777-2779. 10.1093/jac/dks270, 22782489.
59. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D. 10 x ′20 Progress - development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, 56:1685-1694. 3707426, 23599308.
60. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011, 66:48-53. 10.1093/jac/dkq408, 21078604.
61. Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate beta-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother 2013, 68:1825-1831. 10.1093/jac/dkt118, 23580564.
62. Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 2013, 57:5548-5558. 10.1128/AAC.01288-13, 3811277, 23979750.